
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8831067/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Liver Transplantation in Alcohol-related Liver Disease and Alcohol-related Hepatitis. Journal of Clinical and Experimental Hepatology, 2023, 13, 127-138.	0.9	4
2	Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort). Cannabis and Cannabinoid Research, 2022, 7, 677-689.	2.9	6
3	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. Journal of Hepatology, 2022, 76, 275-282.	3.7	33
4	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. BMC Infectious Diseases, 2022, 22, 94.	2.9	6
5	ABO blood group does not influence Childâ€Pugh A cirrhosis outcome: An observational studyÂfrom CIRRAL and ANRS CO12 CIRVIR cohorts. Liver International, 2022, 42, 1386-1400.	3.9	2
6	Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. Gut, 2022, 71, 1856-1866.	12.1	17
7	Effect of rifaximin on infections, acuteâ€onâ€chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFAâ€AH). Liver International, 2022, 42, 1109-1120.	3.9	20
8	Lung Infection Affects Access to Treatment and Short-Term Outcome in Patients With Severe Alcohol-Related Hepatitis Treated With Corticosteroids. American Journal of Gastroenterology, 2022, 117, 1097-1105.	0.4	5
9	Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study. The Lancet Gastroenterology and Hepatology, 2022, 7, 416-425.	8.1	60
10	Morbid obesity increases death and dropout from the liver transplantation waiting list: A prospective cohort study. United European Gastroenterology Journal, 2022, 10, 396-408.	3.8	7
11	Management of alcoholâ€related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines. Liver International, 2022, 42, 1330-1343.	3.9	10
12	Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101459.	1.5	4
13	Acute Liver Injury With Therapeutic Doses of Acetaminophen: A Prospective Study. Hepatology, 2021, 73, 1945-1955.	7.3	36
14	A tool to predict progression of nonâ€alcoholic fatty liver disease in severely obese patients. Liver International, 2021, 41, 91-100.	3.9	2
15	Genomeâ€wide Association Study and Metaâ€analysis on Alcoholâ€Associated Liver Cirrhosis Identifies Genetic Risk Factors. Hepatology, 2021, 73, 1920-1931.	7.3	54
16	Autochthonous hepatitis E as a cause of acute-on-chronic liver failure and death: histopathology can be misleading but transaminases may provide a clue. Swiss Medical Weekly, 2021, 151, w20502.	1.6	2
17	Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance. JHEP Reports, 2021, 3, 100285.	4.9	4
18	ldentification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. Journal of Hepatology, 2021, 75, 1026-1033.	3.7	59

#	Article	IF	CITATIONS
19	Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis. Nature Communications, 2021, 12, 4560.	12.8	37
20	The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcoholâ€Associated Hepatitis. Liver Transplantation, 2021, 27, 1382-1391.	2.4	4
21	Diagnosis and Treatment of Alcohol-Associated Liver Disease. JAMA - Journal of the American Medical Association, 2021, 326, 165.	7.4	144
22	Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101713.	1.5	10
23	Early liver transplantation for acute alcoholic hepatitis: We can't say no. Journal of Hepatology, 2021, 75, 718-722.	3.7	17
24	Loss of hepatocyte identity following aberrant YAP activation: A key mechanism in alcoholic hepatitis. Journal of Hepatology, 2021, 75, 912-923.	3.7	34
25	Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. American Journal of Gastroenterology, 2021, 116, 106-115.	0.4	25
26	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. Hepatology, 2020, 71, 522-538.	7.3	151
27	A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression. Clinical Gastroenterology and Hepatology, 2020, 18, 2315-2323.e6.	4.4	15
28	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. Gut, 2020, 69, 764-780.	12.1	112
29	Liver transplantation in patients with alcohol-related liver disease: current status and future directions. The Lancet Gastroenterology and Hepatology, 2020, 5, 507-514.	8.1	50
30	Combined alcoholic and non-alcoholic steatohepatitis. JHEP Reports, 2020, 2, 100101.	4.9	42
31	Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology, 2020, 159, 1290-1301.e5.	1.3	310
32	Serum Transferrin Is an Independent Predictor of Mortality in Severe Alcoholic Hepatitis. American Journal of Gastroenterology, 2020, 115, 398-405.	0.4	24
33	Personalized surveillance for hepatocellular carcinoma in cirrhosis– using machine learning adapted to HCV status. Journal of Hepatology, 2020, 73, 1434-1445.	3.7	52
34	Intestinal Virome in Patients With Alcoholic Hepatitis. Hepatology, 2020, 72, 2182-2196.	7.3	74
35	Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. Journal of Hepatology, 2020, 73, 1046-1062.	3.7	79
36	IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis. Journal of Hepatology, 2020, 72, 1052-1061.	3.7	35

#	Article	IF	CITATIONS
37	Consequences of TIPSS placement on the body composition of patients with cirrhosis and severe portal hypertension: a large retrospective CTâ€based surveillance. Alimentary Pharmacology and Therapeutics, 2020, 52, 1516-1526.	3.7	40
38	Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. Nature Communications, 2019, 10, 3126.	12.8	124
39	Nucleotide-binding oligomerization domain 1 (NOD1) modulates liver ischemia reperfusion through the expression adhesion molecules. Journal of Hepatology, 2019, 70, 1159-1169.	3.7	17
40	The prognostic impact of cirrhosis on patients receiving maintenance haemodialysis. Alimentary Pharmacology and Therapeutics, 2019, 50, 75-83.	3.7	5
41	Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project. International Journal of Drug Policy, 2019, 72, 61-68.	3.3	23
42	Quality of life in patients with chronic hepatitis C infection: Severe comorbidities and disease perception matter more than liver-disease stage. PLoS ONE, 2019, 14, e0215596.	2.5	17
43	Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation. Journal of Hepatology, 2019, 70, 831-838.	3.7	18
44	Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. BMC Infectious Diseases, 2019, 19, 300.	2.9	5
45	Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. Gastroenterology, 2019, 156, 997-1009.e5.	1.3	100
46	Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet, The, 2019, 393, 1453-1464.	13.7	449
47	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature, 2019, 575, 505-511.	27.8	493
48	The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. European Journal of Gastroenterology and Hepatology, 2019, 31, 393-402.	1.6	12
49	Ductular Reaction Cells Display an Inflammatory Profile and Recruit Neutrophils in Alcoholic Hepatitis. Hepatology, 2019, 69, 2180-2195.	7.3	52
50	Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study. Journal of Hepatology, 2019, 70, 521-530.	3.7	72
51	Endpoints and patient stratification in clinical trials for alcoholic hepatitis. Journal of Hepatology, 2019, 70, 314-318.	3.7	17
52	Nonâ€virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of <scp>ANRS CO</scp> 12 CirVir cohort. Journal of Viral Hepatitis, 2019, 26, 384-396.	2.0	16
53	French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes. Value in Health, 2018, 21, 1218-1225.	0.3	21
54	Impact of a first study of early transplantation in acute alcoholic hepatitis: Results of a nationwide survey in french liver transplantation programs. Liver Transplantation, 2018, 24, 841-844.	2.4	27

#	Article	IF	CITATIONS
55	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. Journal of Hepatology, 2018, 69, 396-405.	3.7	144
56	Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication. Hepatology, 2018, 68, 1245-1259.	7.3	33
57	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncology, The, 2018, 19, 682-693.	10.7	285
58	EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. Journal of Hepatology, 2018, 69, 154-181.	3.7	591
59	Alcohol, liver disease, and transplantation. Current Opinion in Organ Transplantation, 2018, 23, 175-179.	1.6	14
60	Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. European Journal of Gastroenterology and Hepatology, 2018, 30, 569-577.	1.6	15
61	Impact of steatosis and inflammation definitions on the performance of NASH tests. European Journal of Gastroenterology and Hepatology, 2018, 30, 384-391.	1.6	13
62	Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. American Heart Journal, 2018, 198, 4-17.	2.7	49
63	Increased Hepatic PDGF-AA Signaling Mediates Liver Insulin Resistance in Obesity-Associated Type 2 Diabetes. Diabetes, 2018, 67, 1310-1321.	0.6	64
64	Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. Alcohol, 2018, 66, 1-7.	1.7	13
65	Recalibrated MELD and hepatic encephalopathy are prognostic factors in cirrhotic patients with acute variceal bleeding. Liver International, 2018, 38, 469-476.	3.9	24
66	Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology, 2018, 155, 1436-1450.e6.	1.3	183
67	Liver Transplantation for Severe Alcoholic Hepatitis: Where Are We Now?. Liver Transplantation, 2018, 24, 1327-1328.	2.4	1
68	Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo—a Meta-analysis of Individual Data From Controlled Trials. Gastroenterology, 2018, 155, 458-468.e8.	1.3	153
69	The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity. Nature Communications, 2018, 9, 2092.	12.8	63
70	Assessing the cost-effectiveness of hepatitis C screening strategies in France. Journal of Hepatology, 2018, 69, 785-792.	3.7	66
71	Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. Gastroenterology, 2018, 155, 431-442.e10.	1.3	81
72	Alcoholic liver disease. Nature Reviews Disease Primers, 2018, 4, 16.	30.5	660

73Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis., 2018, 68, 349.174Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 775Comparison of Binary Predictive Scoring Systems of Posthepatectomy Liver Failure. Annals of Surgery, 2017, 265, e57-e58.4.2	#	Article	IF	CITATIONS
Comparison of Binary Predictive Scoring Systems of Posthepatectomy Liver Failure. Annals of Surgery,	73	Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. , 2018, 68, 349.		1
	74	Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir) Tj ETQq0 0 0 rgBT /O	verlock 2 12.1	10 Tf 50 702 1
	75		4.2	1

76	Liver transplantation for patients with alcoholic hepatitis. Liver International, 2017, 37, 337-339.	3.9	29
77	Transient elastography alone and in combination with FibroTest [®] for the diagnosis of hepatic fibrosis in alcoholic liver disease. Liver International, 2017, 37, 1697-1705.	3.9	40
78	Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: A prospective study. Hepatology, 2017, 66, 1464-1473.	7.3	149
79	A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso). Journal of Hepatology, 2017, 66, S89.	3.7	49
80	Liver transplantation in the most severely ill cirrhotic patients: A multicenter study in acute-on-chronic liver failure grade 3. Journal of Hepatology, 2017, 67, 708-715.	3.7	276
81	Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. New England Journal of Medicine, 2017, 376, 2134-2146.	27.0	467
82	The negative impact of <scp>HBV</scp> / <scp>HCV</scp> coinfection on cirrhosis and its consequences. Alimentary Pharmacology and Therapeutics, 2017, 46, 1054-1060.	3.7	66
83	Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. Gut, 2017, 66, 1912-1917.	12.1	24
84	Whole transcriptome analysis of ductular reaction from patients with alcoholic hepatitis. Similarities to ductular reaction in DDC mouse model. Journal of Hepatology, 2017, 66, S81.	3.7	0
85	Cirrhosis impacts outcome of hemodialyzed patients and should lead to consider spontaneous		
	liver-kidney transplantation. Journal of Hepatology, 2017, 66, S368.	3.7	0
86		3.7 3.7	0
86 87	liver-kidney transplantation. Journal of Hepatology, 2017, 66, S368. Effectiveness and cost-effectiveness of antiviral treatment initiation in hepatitis C related		
	liver-kidney transplantation. Journal of Hepatology, 2017, 66, S368. Effectiveness and cost-effectiveness of antiviral treatment initiation in hepatitis C related decompensated cirrhosis in France. Journal of Hepatology, 2017, 66, S414-S415. Main drivers of outcome differ between short and long-term in severe alcoholic hepatitis: a	3.7	

90Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. Journal of
Hepatology, 2017, 66, 39-47.3.7100

#	Article	IF	CITATIONS
91	Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. Gastroenterology, 2017, 152, 142-156.e2.	1.3	420
92	Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites. Gastroenterology, 2017, 152, 157-163.	1.3	324
93	Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial Journal of Clinical Oncology, 2017, 35, 4000-4000.	1.6	31
94	A Proof of Concept, Phase II Randomized European Trial, on the Efficacy of ALF-5755, a Novel Extracellular Matrix-Targeted Antioxidant in Patients with Acute Liver Diseases. PLoS ONE, 2016, 11, e0150733.	2.5	8
95	Liver Transplantation for Alcoholic Liver Disease. Transplantation, 2016, 100, 981-987.	1.0	65
96	Reply. Gastroenterology, 2016, 150, 284-285.	1.3	1
97	Su1415 The Tolerability of Sof/VEL for 12 Weeks in >1000 Patients Treated in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies: An Integrated Safety Analysis. Gastroenterology, 2016, 150, S1093.	1.3	0
98	Commonalities and Distinctions Between Alcoholic andÂNonalcoholic Fatty Liver Disease. Gastroenterology, 2016, 150, 1695-1697.	1.3	7
99	Extrahepatic Cancer is the Second Cause of Non Liver-Related Death in Patients with Compensated Viral Cirrhosis and is Associated with Viral Replication (ANRS CO12 CirVir Prospective Cohort). Journal of Hepatology, 2016, 64, S273.	3.7	0
100	Clinical and Social Psychological Profiles of Patients with Chronic Hepatitis C Treated with IFN-Free Regimens in France. Journal of Hepatology, 2016, 64, S468-S469.	3.7	0
101	On Treatment HCV RNA as a Predictor of SVR12 in Patients with Genotype 1–6 HCV Infection Treated with Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks: An Analysis of the Astral-1, Astral-2, and Astral-3 Studies. Journal of Hepatology, 2016, 64, S817.	3.7	1
102	New Recommendations of Baveno Vi Conference for the Screening of Portal Hypertension: An Independent Sequential Validation in Patients with Compensated Viral Cirrhosis Taking into Account Virological Status (Anrs Co12 Cirvir Cohort). Journal of Hepatology, 2016, 64, S178.	3.7	3
103	Cost-Effectiveness and Budget Impact of Interferon-Free Direct-Acting Antiviral (DAA)-Based Regimens for Chronic Hepatitis C Treatment. The French Case. Journal of Hepatology, 2016, 64, S470-S471.	3.7	0
104	The Benefits of Virosuppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort). Journal of Hepatology, 2016, 64, S655-S656.	3.7	0
105	The Tolerability of SOF/VEL for 12 Weeks in >1,000 Patients Treated in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies: An Integrated Safety Analysis. Journal of Hepatology, 2016, 64, S773-S774.	3.7	2
106	Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). Hepatology, 2016, 64, 1136-1147.	7.3	75
107	Prospective Evidence That Hepatocellular Carcinoma Surveillance in Patients with Compensated Viral Cirrhosis Increases the Probability of Curative Treatment and Survival Taking into Account Lead-Time Bias (Anrs Co12 Cirvir Cohort). Journal of Hepatology, 2016, 64, S194-S195.	3.7	2
108	Does Multiorgan Failure Impact Prognosis of Liver Transplantation in Patients with End-Stage Liver Disease? Results of a French Retrospective Multicenter Case-Control Study. Journal of Hepatology, 2016, 64, S537.	3.7	1

#	Article	IF	CITATIONS
109	Transient Elastography and Combination of Fibrotest® and Transient Elastography for Diagnosis of Advanced Fibrosis and Cirrhosis in Patients with Alcoholic Liver Disease: A Prospective Multicenter Cohort Study. Journal of Hepatology, 2016, 64, S718-S719.	3.7	0
110	Costâ€effectiveness and budget impact of interferonâ€free directâ€acting antiviralâ€based regimens for hepatitis <scp>C</scp> treatment: the <scp>F</scp> rench case. Journal of Viral Hepatitis, 2016, 23, 767-779.	2.0	27
111	Su1414 On Treatment HCV RNA as a Predictor of SVR12 in Patients with Genotype 1-6 HCV Infection Treated With Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks: An Analysis of the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies. Gastroenterology, 2016, 150, S1092-S1093.	1.3	0
112	Altered intestinal microbiota as a major driving force in alcoholic steatohepatitis. Gut, 2016, 65, 728-729.	12.1	13
113	Elafibranor, an Agonist of the Peroxisome Proliferatorâ^'Activated Receptorâ^'α andÂâ^'δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology, 2016, 150, 1147-1159.e5.	1.3	847
114	Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology, 2016, 150, 785-790.	1.3	387
115	Perspectives on Treatment for Nonalcoholic Steatohepatitis. Gastroenterology, 2016, 150, 1835-1848.	1.3	71
116	P0794 : Relationship between HCV genotype, liver co-morbidities and fibrosis in the French cohort ANRS CO22 HEPATHER. Journal of Hepatology, 2015, 62, S630-S631.	3.7	0
117	P1093 : Characterization of acetaminophen therapeutic misadventure: A single centre experience. Journal of Hepatology, 2015, 62, S759-S760.	3.7	0
118	PO468 : Negative impact of HBV/HCV coinfection on HBV or HCV monoinfection: Data from the French cohort – ANRS CO22 hepather. Journal of Hepatology, 2015, 62, S488-S489.	3.7	1
119	Should patients with alcoholic hepatitis be considered for liver transplantation?. Clinical Liver Disease, 2015, 6, 149-152.	2.1	6
120	Brief Report: Genetics of Alcoholic Cirrhosis— <scp>G</scp> enom <scp>ALC</scp> Multinational Study. Alcoholism: Clinical and Experimental Research, 2015, 39, 836-842.	2.4	29
121	P0150 : Liver cirrhosis is independently associated with mortality in patients with bacterial endocarditis: Results of a case control multicenter study of 202 cases. Journal of Hepatology, 2015, 62, S358.	3.7	0
122	Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology, 2015, 62, 762-772.	7.3	230
123	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. New England Journal of Medicine, 2015, 373, 2599-2607.	27.0	945
124	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. New England Journal of Medicine, 2015, 373, 2608-2617.	27.0	740
125	Reply to "Albumin infusion in cirrhotic patients with non-SBP infections: End of the story?― Journal of Hepatology, 2015, 63, 768-769.	3.7	0

126 Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir) Tj ETQq0 0 0 rgBT /0.987 10 Tf 50 62

#	Article	lF	CITATIONS
127	Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial. Lancet Infectious Diseases, The, 2015, 15, 387-396.	9.1	67
128	O017 : Effectiveness of treatment initiation based on fibrosis stage assessed by methods of fibrosis diagnosis in terms of 5-year incidence of morbi-mortality. Journal of Hepatology, 2015, 62, S198.	3.7	1
129	LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*. Journal of Hepatology, 2015, 62, S258-S259.	3.7	26
130	LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather. Journal of Hepatology, 2015, 62, S278.	3.7	18
131	P0745 : EQ-5D utility index in French patients with chronic hepatits C (CHC) infection: severe comorbidities and perceived progression of CHC infection matter more than actual liver disease stage. Journal of Hepatology, 2015, 62, S605.	3.7	4
132	P0795 : Safety and efficacy of sofosbuvir-containing regimens in the French observational cohort ANRS CO22 HEPATHER. Journal of Hepatology, 2015, 62, S631-S632.	3.7	8
133	P1087 : Prediction of death as a continuum of risk of mortality in severe alcoholic hepatitis based on baseline and dynamic models. Journal of Hepatology, 2015, 62, S757-S758.	3.7	0
134	P1266 : Human albumin use in cirrhotic patients in France: Results of the national "Albu-live―survey. Journal of Hepatology, 2015, 62, S833.	3.7	0
135	Combining Data From Liver Disease Scoring Systems Better Predicts Outcomes of Patients With Alcoholic Hepatitis. Gastroenterology, 2015, 149, 398-406.e8.	1.3	134
136	Therapeutic management of alcoholic hepatitis. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, S41-S45.	1.5	6
137	Recurrent Alcoholic Cirrhosis In Severe Alcoholic Relapse After Liver Transplantation: A Frequent and Serious Complication. American Journal of Gastroenterology, 2015, 110, 1160-1166.	0.4	121
138	Patients with acute liver failure listed for superurgent liver transplantation in France: Reevaluation of the clichyâ€villejuif criteria. Liver Transplantation, 2015, 21, 512-523.	2.4	49
139	Trends in the management and burden of alcoholic liver disease. Journal of Hepatology, 2015, 62, S38-S46.	3.7	254
140	Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infectious Diseases, The, 2015, 15, 397-404.	9.1	267
141	Alcoholic liver disease: mechanisms of injury and targeted treatment. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 231-242.	17.8	643
142	Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. Gastroenterology, 2015, 149, 379-388.	1.3	608
143	Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission. Journal of Antimicrobial Chemotherapy, 2015, 70, 2108-2120.	3.0	92
144	Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis. Gut, 2015, 64, 1949-1960.	12.1	137

#	Article	IF	CITATIONS
145	Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. Future Oncology, 2015, 11, 2553-2562.	2.4	13
146	Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding. Hepatology, 2015, 61, 1024-1032.	7.3	23
147	Prevalence of renal abnormalities in chronic <scp>HBV</scp> infection: The <scp>HARPE</scp> study. Liver International, 2015, 35, 148-155.	3.9	35
148	Drug-Eluting Beads Loaded With Doxorubicin (DEBDOX) Chemoembolisation Before Liver Transplantation for Hepatocellular Carcinoma: An Imaging/Histologic Correlation Study. CardioVascular and Interventional Radiology, 2015, 38, 685-692.	2.0	10
149	Association between the <i>PNPLA3</i> (rs738409 C>C) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology, 2014, 59, 2170-2177.	7.3	193
150	Relevance of the ISGLS Definition of Posthepatectomy Liver Failure in Early Prediction of Poor Outcome After Liver Resection. Annals of Surgery, 2014, 260, 865-870.	4.2	56
151	O85 SHOULD WE AWAIT INTERFERON-FREE REGIMENS TO TREAT HCV GENOTYPE 1 TREATMENT-NAIVE PATIENTS? A COST-EFFECTIVENESS ANALYSIS (ANRS 12188). Journal of Hepatology, 2014, 60, S35.	3.7	1
152	Precise evaluation of liver histology by computerized morphometry shows that steatosis influences liver stiffness measured by transient elastography in chronic hepatitis C. Journal of Gastroenterology, 2014, 49, 527-537.	5.1	53
153	Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). Journal of Hepatology, 2014, 61, 7-14.	3.7	57
154	Improved fibrosis staging by elastometry and blood test in chronic hepatitis C. Liver International, 2014, 34, 907-917.	3.9	28
155	Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA. Gastroenterology, 2014, 146, 1240-1248.	1.3	151
156	Reply. Gastroenterology, 2014, 147, 936-937.	1.3	0
157	A Histologic Scoring System for Prognosis of Patients With AlcoholicÂHepatitis. Gastroenterology, 2014, 146, 1231-1239.e6.	1.3	353
158	Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: A modelling approach. Digestive and Liver Disease, 2014, 46, 157-163.	0.9	15
159	P957 FINAL ANALYSIS OF AETIOLOGY/COMORBIDITIES IN EUROPEAN PATIENTS FROM THE GIDEON (GLOBAL) Tj	ETQq1 1 3.7	0.784314 rgE 0
160	O139 ALCOHOLIC HEPATITIS RESISTANT TO MEDICAL THERAPY IS CHARACTERIZED BY AN ALTERED DIFFERENTIATION OF HEPATIC PROGENITORS UNDER THE INFLUENCE OF EXTRACELLULAR MATRIX. Journal of Hepatology, 2014, 60, S59.	3.7	1
161	Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. New England Journal of Medicine, 2014, 370, 1993-2001.	27.0	752
162	Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: A modeling approach. Hepatology, 2014, 59, 1471-1481.	7.3	52

#	Article	IF	CITATIONS
163	Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding to Reduce Nonalcoholic Fatty Liver Disease. Annals of Surgery, 2014, 260, 893-899.	4.2	204
164	Final analysis of European patients from the Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) study: Baseline characteristics and staging systems Journal of Clinical Oncology, 2014, 32, 4088-4088.	1.6	0
165	405 HARPE STUDY: PREVALENCE OF RENAL ABNORMALITIES IN CHRONIC HBV INFECTION. Journal of Hepatology, 2013, 58, S166-S167.	3.7	0
166	101 TENOFOVIR DF (TDF) COMPARED TO EMTRICITABINE (FTC)/TDF IN HBeAg-POSITIVE, CHRONIC HEPATITIS B (CHB) VIRUSINFECTED PATIENTS IN THE IMMUNE TOLERANT (IT) PHASE. Journal of Hepatology, 2013, 58, S45.	3.7	5
167	Albumin Dialysis With a Noncell Artificial Liver Support Device in Patients With Acute Liver Failure. Annals of Internal Medicine, 2013, 159, 522.	3.9	231
168	AST/ALT ratio is not an index of liver fibrosis in chronic hepatitis C when aminotransferase activities are determinate according to the international recommendations. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 467-472.	1.5	18
169	Prednisolone With vs Without Pentoxifylline and Survival of Patients With Severe Alcoholic Hepatitis. JAMA - Journal of the American Medical Association, 2013, 310, 1033.	7.4	181
170	A French national survey on the use of antibiotic prophylaxis in cirrhotic patients. Liver International, 2013, 33, 389-397.	3.9	12
171	Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C. Journal of Medical Virology, 2013, 85, 1191-1198.	5.0	2
172	Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy. Clinica Chimica Acta, 2013, 415, 63-68.	1.1	14
173	Bariatric surgery for curing NASH in the morbidly obese?. Journal of Hepatology, 2013, 58, 1249-1251.	3.7	41
174	661 ULTRASONOGRAPHIC (US) SCREENING OF HEPATOCELLULAR CARCINOMA (HCC) IN COMPENSATED CIRRHOSIS DUE TO HEPATITIS C VIRUS (HCV) IMPROVES SURVIVAL: A MODELING APPROACH. Journal of Hepatology, 2013, 58, S269.	3.7	0
175	809 IMMEDIATE OR DELAYED TREATMENT INITIATION WITH "PREVIR―CONTAINING REGIMENS IN HCV-INFECTED NAIVE GENOTYPE 1 (G1) PATIENTS WITHOUT SEVERE FIBROSIS? A COST-EFFECTIVENESS ANALYSIS (ANRS N°12188). Journal of Hepatology, 2013, 58, S331.	3.7	2
176	117 SPONTANEOUS DECREASE IN LIVER INJURY DOES NOT STRONGLY PREDICT EVOLUTION OF PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS TREATED WITH CORTICOSTEROIDS. Journal of Hepatology, 2013, 58, S52-S53.	3.7	1
177	ASMase is required for chronic alcohol induced hepatic endoplasmic reticulum stress and mitochondrial cholesterol loading. Journal of Hepatology, 2013, 59, 805-813.	3.7	89
178	Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. Journal of Clinical Oncology, 2013, 31, 3509-3516.	1.6	544
179	HCV burden in Europe and the possible impact of current treatment. Digestive and Liver Disease, 2013, 45, S314-S317.	0.9	14
180	49 LIFETIME COSTS ATTRIBUTABLE TO CHRONIC HEPATITIS C FROM THE FRENCH HEALTHCARE PERSPECTIVE (ANRS N°12188). Journal of Hepatology, 2013, 58, S21-S22.	3.7	14

#	Article	IF	CITATIONS
181	765 TWELVE-MONTHS ENTECAVIR LONGITUDINAL CHANGES IN LIVER FIBROSIS, ACTIVITY AS PER FibroTest-FibroMax AND LIVER STIFFNESS MEASUREMENTS IN CHRONIC HEPATITIS B. STEATOSIS IMPACT ON FIBROSIS REGRESSION. Journal of Hepatology, 2013, 58, S311-S312.	3.7	0
182	287 ICAM-1 AND VCAM-1 EXPRESSION IN HEPATOCYTE IS REGULATED BY NOD1 PATHWAY. Journal of Hepatology, 2013, 58, S121-S122.	3.7	0
183	1350 GASTRIC BYPASS IS EFFICIENT ON MEBOLIC AND LIVER STEATOSIS AFTER LAPAROSCOPIC GASTRIC BANDING RELAPSE. Journal of Hepatology, 2013, 58, S543.	3.7	0
184	868 TREATMENT WITH TELAPREVIR-BASED THERAPY AFTER EXPOSURE TO PEG-IFN/RBV IN THE REALIZE STUDY: RESULTS FROM THE PHASE IIIB C219 ROLLOVER STUDY. Journal of Hepatology, 2013, 58, S356-S357.	3.7	0
185	Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial. Hepatology, 2013, 57, 1153-1162.	7.3	452
186	Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology, 2013, 57, 974-984.	7.3	67
187	Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology, 2013, 57, 1182-1191.	7.3	466
188	Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C. Clinical Chemistry and Laboratory Medicine, 2012, 50, 693-9.	2.3	28
189	Management of alcoholic hepatitis. Journal of Hepatology, 2012, 56, S39-S45.	3.7	103
190	6 BARIATRIC SURGERY AN EFFICIENT TREATMENT FOR PATIENT WITH STEATOHEPATITIS. Journal of Hepatology, 2012, 56, S3.	3.7	0
191	8 SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS) TJ ETQq1 1 0.	7847814	rgB ढ ‡Overlc∂
192	100 BASELINE MODELS HELP IN IDENTIFYING RESPONDERS TO CORTICOSTEROIDS IN SEVERE ALCOHOLIC HEPATITIS: A MULTICENTER STUDY ON MORE THAN 600 PATIENTS. Journal of Hepatology, 2012, 56, S44.	3.7	0
193	EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease. Journal of Hepatology, 2012, 57, 399-420.	3.7	602
194	1021 GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HEPATOCELLULAR CARCINOMA (HCC) AND OF ITS TREATMENT WITH SORAFENIB (GIDEON): IMPACT OF LIVER DYSFUNCTION ON SORAFENIB TREATMENT IN EUROPE. Journal of Hepatology, 2012, 56, S399-S400.	3.7	30
195	1034 REAL-WORLD MANAGEMENT OF HCC WITH SORAFENIB AND TACE IN EUROPE FROM GIDEON (GLOBAL) Tj Hepatology, 2012, 56, S404-S405.	ETQq1 3.7	1 0.784314 1
196	1357 PENTOXIFYLLINE DOES NOT IMPROVE SHORT-TERM SURVIVAL IN SEVERE ALCOHOLIC HEPATITIS IN COMBINATION WITH CORTICOSTEROIDS: RESULTS OF A RANDOMIZED CONTROLLED TRIAL. Journal of Hepatology, 2012, 56, S533-S534.	3.7	4
197	1358 A NEW FORMULA OF THE LILLE MODEL USING INR. Journal of Hepatology, 2012, 56, S534.	3.7	2
198	1094 100% SVR IN IL28B CC PATIENTS TREATED WITH 12 WEEKS OF TELAPREVIR, PEGINTERFERON AND RIBAVIRIN IN THE PROVE2 TRIAL. Journal of Hepatology, 2012, 56, S430-S431.	3.7	37

#	Article	IF	CITATIONS
199	1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY. Journal of Hepatology, 2012, 56, S549.	3.7	76
200	1316 METABOLIC COMORBIDITIES IN A LARGE FRENCH REAL-LIFE COHORT OF PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN. Journal of Hepatology, 2012, 56, S518-S519.	3.7	0
201	Reply to: "HCV infection, HOMA index and sustained virological response: The step we need to take before moving forward― Journal of Hepatology, 2012, 57, 473.	3.7	0
202	Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. Journal of Hepatology, 2012, 57, 39-46.	3.7	40
203	Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: A model-based analysis. Journal of Hepatology, 2012, 57, 260-266.	3.7	22
204	Randomised clinical trial: enteral nutrition does not improve the longâ€ŧerm outcome of alcoholic cirrhotic patients with jaundice. Alimentary Pharmacology and Therapeutics, 2012, 35, 1166-1174.	3.7	41
205	Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir. Gastroenterology, 2012, 143, 608-618.e5.	1.3	179
206	Predicted Effects of Treatment for HCV Infection Vary Among European Countries. Gastroenterology, 2012, 143, 974-985.e14.	1.3	107
207	Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir). Clinics and Research in Hepatology and Gastroenterology, 2012, 36, 214-221.	1.5	30
208	1301 BARIATRIC SURGERY CAN BE PROPOSED TO MORBID OBESE HIGHLY SELECTED WITH COMPENSATED CIRRHOSIS. Journal of Hepatology, 2012, 56, S513.	3.7	0
209	Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis. Gut, 2012, 61, 290-296.	12.1	17
210	Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis. British Journal of Surgery, 2012, 99, 855-863.	0.3	130
211	Metaâ€analysis: the impact of <scp>IL</scp> 28 <scp>B</scp> polymorphisms on rapid and sustained virological response in <scp>HCV</scp> â€2 and â€3 patients. Alimentary Pharmacology and Therapeutics, 2012, 36, 353-362.	3.7	37
212	Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology, 2012, 55, 58-67.	7.3	112
213	Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data. PLoS ONE, 2012, 7, e30325.	2.5	117
214	Telaprevir for Retreatment of HCV Infection. New England Journal of Medicine, 2011, 364, 2417-2428.	27.0	1,466
215	1362 THE AVAILABILITY OF DIRECT ACTING ANTIVIRALS (DAA) IN 2012: A FRENCH MODEL-BASED ANALYSIS OF THE INCREASED NUMBER OF PATIENTS TREATED FOR CHRONIC HCV INFECTION. Journal of Hepatology, 2011, 54, S539-S540.	3.7	1
216	1163 IMPACT OF HBV AND HCV IN KIDNEY TRANSPLANTED PATIENTS: ACTUALIZATION OF PREVALENCE AND PROGNOSTIC DATA. Journal of Hepatology, 2011, 54, S459-S460.	3.7	0

#	Article	IF	CITATIONS
217	OC-17 HCV burden in Europe: Impact of national treatment practices on future HCV-related morbidity and mortality through a modeling approach. Digestive and Liver Disease, 2011, 43, S70.	0.9	5
218	Early Liver Transplantation for Severe Alcoholic Hepatitis. New England Journal of Medicine, 2011, 365, 1790-1800.	27.0	792
219	High-Dose Pegylated Interferon- \hat{I}_{\pm} and Ribavirin in Nonresponder Hepatitis C Patients and Relationship With IL-28B Genotype (SYREN Trial). Gastroenterology, 2011, 141, 119-127.	1.3	26
220	Boceprevir for Untreated Chronic HCV Genotype 1 Infection. New England Journal of Medicine, 2011, 364, 1195-1206.	27.0	2,352
221	A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. Journal of Hepatology, 2011, 54, 1011-1019.	3.7	278
222	Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin. Journal of Hepatology, 2011, 55, 989-995.	3.7	4
223	Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: A meta-analysis. Journal of Hepatology, 2011, 55, 1187-1194.	3.7	77
224	Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut, 2011, 60, 255-260.	12.1	363
225	122 HCV BURDEN IN EUROPE: IMPACT OF NATIONAL TREATMENT PRACTICES ON FUTURE HCV-RELATED MORBIDITY AND MORTALITY THROUGH A MODELING APPROACH. Journal of Hepatology, 2011, 54, S54.	3.7	6
226	501 PROGNOSTIC SCORES ARE EFFICIENT IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS TREATED WITH CORTICOSTEROIDS: COMPARISON OF AVAILABLE MODELS. Journal of Hepatology, 2011, 54, S204-S205.	3.7	0
227	510 PREVENTION OF LIVER ISCHEMIA/REPERFUSION INJURY BY MODULATING INTESTINAL FLORA: AN ATTRACTIVE APPROACH. Journal of Hepatology, 2011, 54, S209.	3.7	1
228	626 ASSESSMENT OF RESPONSE TO SORAFENIB IN HEPATOCELLULAR CARCINOMA: PROGNOSTIC VALUE OF TUMORAL DENSITY AND ARTERIAL ENHANCEMENT MEASUREMENTS IN TARGET LESIONS. Journal of Hepatology, 2011, 54, S254.	3.7	0
229	715 BASELINE GENOTYPE AND HBSAG WERE FOUND TO HAVE SIGNIFICANT ASSOCIATION WITH HBEAG SEROCONVERSION FOLLOWING UP TO 4 YEARS OF TENOFOVIR DISOPROXIL FUMARATE TREATMENT. Journal of Hepatology, 2011, 54, S287.	3.7	0
230	855 DIAGNOSTIC VALUE OF BIOMARKERS (FIBROTEST, ACHTEST, STEATOTEST AND NASHTEST) FOR THE PREDICTION OF LIVER INJURY IN 494 PATIENTS WITH SEVERE OBESITY. Journal of Hepatology, 2011, 54, S341.	3.7	0
231	Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. European Journal of Gastroenterology and Hepatology, 2011, 23, 499-506.	1.6	82
232	Partial graft recovery following eradication of hepatitis E virus infection after successful islet allograft transplantation. Transplant International, 2011, 24, e13-e15.	1.6	5
233	Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy. Alimentary Pharmacology and Therapeutics, 2011, 34, 454-461.	3.7	27
234	Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Alimentary Pharmacology and Therapeutics, 2011, 34, 1193-1201.	3.7	102

#	Article	IF	CITATIONS
235	Assessing bone status in patients awaiting liver transplantation. Joint Bone Spine, 2011, 78, 387-391.	1.6	49
236	Management of alcohol dependence in transplant candidates: We are far away from the objective line. Liver Transplantation, 2011, 17, 492-493.	2.4	9
237	Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities. Hepatology, 2011, 54, 1987-1997.	7.3	309
238	Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. European Journal of Gastroenterology and Hepatology, 2010, 22, 1050-1057.	1.6	39
239	Sclérothérapie par entéroscopie de varices jéjunales hémorragiques. Acta Endoscopica, 2010, 40, 193-194.	0.0	0
240	Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow-up study. Hepatology, 2010, 51, 210-218.	7.3	458
241	Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology, 2010, 52, 1201-1207.	7.3	63
242	Long-term metabolic outcome and quality of life after laparoscopic adjustable gastric banding in obese patients with type 2 diabetes mellitus or impaired fasting glucose. British Journal of Surgery, 2010, 97, 884-891.	0.3	49
243	Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferonâ€alphaâ€2bâ€ribavirin combination therapy. Journal of Medical Virology, 2010, 82, 1640-1646.	5.0	5
244	Optimization and robustness of blood tests for liver fibrosis and cirrhosis. Clinical Biochemistry, 2010, 43, 1315-1322.	1.9	42
245	1024 EFFICACY AND SAFETY OF THE COMBINATION OF ENTECAVIR (ETV)-TENOFOVIR (TDF) IN THE TREATMENT OF CHRONIC HEPATITIS B (CHB): A NATIONWIDE, RETROSPECTIVE STUDY. Journal of Hepatology, 2010, 52, S396.	3.7	2
246	2007 4 WEEK THERAPY WITH THE NON-NUCLEOSIDIC POLYMERASE INHIBITOR BI207127 IN COMBINATION WITH PEGINTERFERON-ALFA2A AND RIBAVIRIN IN TREATMENT NAIVE AND TREATMENT EXPERIENCED CHRONIC HCV GT1 PATIENTS. Journal of Hepatology, 2010, 52, S466.	3.7	15
247	1161 A PROSPECTIVE STUDY OF ACETAMINOPHEN THERAPEUTIC MISADVENTURE: DURATION OF INTAKE AND HEAVY DRINKING ARE TWO KEY FACTORS. Journal of Hepatology, 2010, 52, S448-S449.	3.7	0
248	1054 MODERATE AND EXCESSIVE ALCOHOL INTAKE IMPACT TRANSPLANT-FREE SURVIVAL: A LONGITUDINAL STUDY IN HCV CIRRHOTIC PATIENTS. Journal of Hepatology, 2010, 52, S408.	3.7	0
249	Neutrophil Migration During Liver Injury Is Under Nucleotide-Binding Oligomerization Domain 1 Control. Gastroenterology, 2010, 138, 1546-1556.e5.	1.3	32
250	Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: A meta-analysis. Journal of Hepatology, 2010, 52, 25-31.	3.7	64
251	The use of corticosteroids in severe alcohol hepatitis: We need to look beyond this controversy. Journal of Hepatology, 2010, 53, 392-393.	3.7	11
252	Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clinica Chimica Acta, 2010, 411, 86-91.	1.1	34

#	Article	IF	CITATIONS
253	29 EARLY TRANSPLANTATION IMPROVES SURVIVAL OF NON-RESPONDERS TO CORTICOSTEROIDS IN SEVERE ALCOHOLIC HEPATITIS: A CHALLENGE TO THE 6 MONTH RULE OF ABSTINENCE. Journal of Hepatology, 2010, 52, S13.	3.7	9
254	252 2-LOG DROP IN VIRAL LOAD AT ONE MONTH: A NEW STOPPING RULE IN RELAPSERS AND NON-RESPONDERS HCV PATIENTS RE-TREATED WITH PEGYLATED-IFN AND RIBAVIRIN?. Journal of Hepatology, 2010, 52, S106.	3.7	0
255	345 DIAGNOSTIC VALUE OF LIVER INJURY BIOMARKERS, FIBROTEST (FT), STEATOTEST (ST), NASHTEST (NT) IN PATIENTS WITHOUT ADVANCED DISEASE UNDERGOING BARIATRIC SURGERY. Journal of Hepatology, 2010, 52, S144.	3.7	0
256	396 ASSESSMENT OF LIVER STIFFNESS (LS) IN THE RELAPSE OF ALCOHOLIC LIVER DISEASE (RALD) AFTER LIVER TRANSPLANTATION (LT). Journal of Hepatology, 2010, 52, S162-S163.	3.7	0
257	Immediate Listing for Liver Transplantation Versus Standard Care for Child–Pugh Stage B Alcoholic Cirrhosis. Annals of Internal Medicine, 2009, 150, 153.	3.9	64
258	Primary sarcoma of the liver and transplantation: a case study and literature review. Rare Tumors, 2009, 1, 93-95.	0.6	4
259	Peroxisome Proliferator-Activated Receptors in HBV-Related Infection. PPAR Research, 2009, 2009, 1-6.	2.4	12
260	Peroxisome Proliferator-Activated Receptors in HCV-Related Infection. PPAR Research, 2009, 2009, 1-5.	2.4	17
261	Mycophenolate Mofetil Monotherapy for Severe Side Effects of Calcineurin Inhibitors Following Liver Transplantation. American Journal of Transplantation, 2009, 9, 610-613.	4.7	24
262	Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation. Gastroenterologie Clinique Et Biologique, 2009, 33, 361-369.	0.9	41
263	Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. Hepatology, 2009, 50, 1351-1359.	7.3	24
264	Changes of serumâ€associated fucosylated glycoproteins and changes in glycosylation of IgA in human cirrhosis. Proteomics - Clinical Applications, 2009, 3, 609-622.	1.6	4
265	A 2â€log drop in viral load at 1 month is the best predictor of sustained response in HCV patients with normal ALT: a kinetic prospective study. Journal of Viral Hepatitis, 2009, 16, 500-505.	2.0	11
266	Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection. New England Journal of Medicine, 2009, 360, 1839-1850.	27.0	1,004
267	Effect of binge drinking on the liver: an alarming public health issue?. Gut, 2009, 58, 613-617.	12.1	111
268	Modelling the past, current and future HCV burden in France: detailed analysis and perspectives. Statistical Methods in Medical Research, 2009, 18, 233-252.	1.5	17
269	Alcoholic Hepatitis. New England Journal of Medicine, 2009, 360, 2758-2769.	27.0	799
270	Prospective Study of the Long-Term Effects of Bariatric Surgery on Liver Injury in Patients Without Advanced Disease. Gastroenterology, 2009, 137, 532-540.	1.3	440

#	Article	IF	CITATIONS
271	Infection in Patients With Severe Alcoholic Hepatitis Treated With Steroids: Early Response to Therapy Is the Key Factor. Gastroenterology, 2009, 137, 541-548.	1.3	305
272	21 TWO YEARS SAFETY AND EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH HBV-INDUCED CIRRHOSIS. Journal of Hepatology, 2009, 50, S10-S11.	3.7	6
273	47 A MULTICENTRIC, DOUBLE-BLIND, RANDOMISED- CONTROLLED TRIAL (RCT) OF HIGH DOSE URSODEOXYCHOLIC ACID IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH). Journal of Hepatology, 2009, 50, S21.	3.7	6
274	66 PROSPECTIVE EVALUATION OF SORAFENIB (SO) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): DOES CHILD SCORE B INFLUENCE SAFETY?. Journal of Hepatology, 2009, 50, S28.	3.7	1
275	123 EFFICACY AND SAFETY OF AN INTENSIFIED REGIMEN OF PEGYLATED INTERFERON ALFA-2A PLUS RIBAVIRIN IN HCV GENOTYPE 1 NON-RESPONDERS: AN INTERIM ANALYSIS OF THE SYREN TRIAL. Journal of Hepatology, 2009, 50, S50.	3.7	0
276	201 CORTICOSTEROIDS IMPROVE 28-DAY SURVIVAL IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS: INDIVIDUAL DATA ANALYSIS OF THE LAST 5 RANDOMIZED CONTROLLED TRIALS. Journal of Hepatology, 2009, 50, S82-S83.	3.7	0
277	202 CIRRHOSIS IS A MAJOR PROGNOSTIC FACTOR OF SURVIVAL DIALYZED PATIENTS: THE NEPHRONORD NETWORK STUDY. Journal of Hepatology, 2009, 50, S83.	3.7	0
278	203 TAFI DEFICIENCY AND ENDOTHELIAL CELL ACTIVATION PLAY A KEY ROLE IN COAGULATION DISORDERS OF PATIENTS WITH SEVERE ACUTE-ON-CHRONIC LIVER FAILURE TREATED BY MARS® SYSTEM. Journal of Hepatology, 2009, 50, S83.	3.7	0
279	214 PREGNANCY IN WOMEN WITH PORTAL VEIN CAVERNOMA (PVC): MATERNAL AND FOETAL MANAGEMENT AND OUTCOME. Journal of Hepatology, 2009, 50, S87.	3.7	0
280	220 PREDICTIVE FACTORS OF TRANSPLANT FREE SURVIVAL IN PATIENTS WITH FULMINANT AND SUBFULMINANT HEPATIC FAILURE: RESULTS FROM A RANDOMIZED CONTROLLED MULTICENTER TRIAL. Journal of Hepatology, 2009, 50, S89-S90.	3.7	18
281	606 ANTI-VIRAL THERAPY IN HAEMODIALYZED HCV PATIENTS: EFFICACY, TOLERANCE AND TREATMENT STRATEGY. Journal of Hepatology, 2009, 50, S223.	3.7	0
282	703 BACTERIAL RECEPTOR NOD1 REGULATES THE NEUTROPHIL MIGRATION MACHINERY DURING LIVER INJURY. Journal of Hepatology, 2009, 50, S258.	3.7	0
283	Etiology, Management, and Outcome of the Budd-Chiari Syndrome. Annals of Internal Medicine, 2009, 151, 167.	3.9	422
284	NOD2: a potential target for regulating liver injury. Laboratory Investigation, 2008, 88, 318-327.	3.7	41
285	Treatment of severe forms of alcoholic hepatitis: Where are we going?. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, S60-S62.	2.8	12
286	PIN4 A MARKOV MODELTO ESTIMATE THE IMPACT ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) AND NORMALTRANSAMINASES (ALT-N) TREATED WITH PEGYLATED BITHERAPY. Value in Health, 2008, 11, A429.	0.3	0
287	Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. Journal of Hepatology, 2008, 48, 465-470.	3.7	148
288	Impact of viral eradication on mortality related to hepatitis C: A modeling approach in France. Journal of Hepatology, 2008, 49, 175-183.	3.7	46

#	Article	IF	CITATIONS
289	Fatal Hemophagocytic Syndrome Related to Human Herpesvirus-6 Reinfection Following Liver Transplantation: A Case Report. Transplantation Proceedings, 2008, 40, 3791-3793.	0.6	19
290	32 SERUM PROTEIN PROFILING OF ALCOHOLIC HEPATITIS USING MASS SPECTROMETRY (SELDI-TOF MS) TJ ETQO Hepatology, 2008, 48, S15.	0 0 0 rgB 3.7	T /Overlock 2 0
291	34 PROSPECTIVE SCREENING OF INFECTION IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS TREATED WITH STEROIDS: EARLY RESPONSE TO THERAPY IS THE KEY FACTOR. Journal of Hepatology, 2008, 48, S15-S16.	3.7	2
292	75 TENOFOVIR DISOPROXIL FUMARATE (TDF) IS HIGHLY ACTIVE FOR TREATMENT OF CHRONIC HEPATITIS B IN SUBJECTS WITH CIRRHOSIS. Journal of Hepatology, 2008, 48, S33.	3.7	9
293	220 ACETAMINOPHEN THERAPEUTIC MISADVENTURE: A PROSPECTIVE STUDY. Journal of Hepatology, 2008, 48, S91.	3.7	1
294	950 TOLERANCE AND EFFICACY OF THE MARS SYSTEM IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS NON-RESPONDERS TO STEROIDS: A PILOT STUDY. Journal of Hepatology, 2008, 48, S355-S356.	3.7	3
295	Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. Hepatology, 2008, 47, 1604-1614.	7.3	266
296	Impact of Impaired Aerobic Capacity on Liver Transplant Candidates. Transplantation, 2008, 86, 1077-1083.	1.0	114
297	Â-Opioid receptor activation prevents acute hepatic inflammation and cell death. Gut, 2007, 56, 974-981.	12.1	27
298	[30] INVOLVEMENT OF NOD SIGNALLING IN HEPATOCYTE AND IMMUNE CELLS DURING HEPATITIS. Journal of Hepatology, 2007, 46, S15.	3.7	0
299	[35] LIVER TRANSPLANTATION (LT) FOR CHOLANGIO-CARCINOMA (CC): LONG-TERM RESULTS IN 42 PATIENTS. Journal of Hepatology, 2007, 46, S17.	3.7	0
300	[47] THE LONG TERM BENEFITS OF BARIATRIC SURGERY CORRELATED TO INSULIN RESISTANCE: A PROSPECTIVE STUDY WITH 5 YEARS OF FOLLOW UP. Journal of Hepatology, 2007, 46, S23.	3.7	0
301	[153] MYCOPHENOLIC ACID (MPA) AUC(0-12h) IN STABLE LIVER TRANSPLANT PATIENTS TREATED WITH A MONOTHERAPY OF MYCOPHENOLATE MOFETIL (MMF) FOR CALCINEURIN INHIBITORS (CNI) INDUCED NEPHROTOXICITY. Journal of Hepatology, 2007, 46, S68.	3.7	0
302	[582] VIRAL KINETICS CAN PREDICT VIROLOGICAL RESPONSE IN HCV PATIENTS WITH NORMAL ALT TREATED WITH PEGYLATED IFN ALFA-2b AND RIBAVIRIN: A PROSPECTIVE STUDY. Journal of Hepatology, 2007, 46, S221.	3.7	0
303	Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology, 2007, 45, 1275-1281.	7.3	136
304	The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology, 2007, 45, 1348-1354.	7.3	598
305	Comparison of two techniques of transarterial chemoembolization before liver transplantation for hepatocellular carcinoma: A case-control study. Liver Transplantation, 2007, 13, 665-671.	2.4	30
306	A patient with alcoholic liver failure referred for liver transplantation. Liver Transplantation, 2007, 13, S83-S86.	2.4	8

#	Article	IF	CITATIONS
307	Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features. Alimentary Pharmacology and Therapeutics, 2007, 25, 1047-1054.	3.7	123
308	92 Prediction of mortality in severe alcoholic hepatitis: Validation of lille model and comparison to other prognostic scores. Journal of Hepatology, 2006, 44, S41.	3.7	0
309	698 Histological features associated with fibrosis progression occur in a particular subgroup of heavy drinkers. Journal of Hepatology, 2006, 44, S257.	3.7	Ο
310	The Evolution of Severe Steatosis After Bariatric Surgery Is Related to Insulin Resistance. Gastroenterology, 2006, 130, 1617-1624.	1.3	136
311	Uncovered Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites. Gastroenterology, 2006, 130, 1372-1373.	1.3	1
312	Mass spectrometric approach for screening modifications of total serum N-glycome in human diseases: application to cirrhosis. Glycobiology, 2006, 16, 281-293.	2.5	72
313	Anticoagulation Therapy May Reverse Biliary Abnormalities Due to Acute Portal Thrombosis. Digestive Diseases and Sciences, 2006, 51, 11-17.	2.3	6
314	Extensive portal vein thrombosis related to abdominal trauma. Gastroenterologie Clinique Et Biologique, 2006, 30, 314-316.	0.9	12
315	Consensus conference: Indications for Liver Transplantation, January 19 and 20, 2005, Lyon-Palais Des Congrès. Liver Transplantation, 2006, 12, 998-1011.	2.4	88
316	Conversion to sirolimus: A useful strategy for recalcitrant cutaneous viral warts in liver transplant recipient. Liver Transplantation, 2006, 12, 1883-1887.	2.4	31
317	Phase II Trial of Docetaxel Therapy in Patients with Advanced Hepatocellular Carcinoma. Oncology, 2006, 70, 154-158.	1.9	29
318	Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis. Liver International, 2005, 25, 349-356.	3.9	113
319	Usefulness of routine analysis of ascitic fluid at the time of therapeutic paracentesis in asymptomatic outpatients. Gastroenterologie Clinique Et Biologique, 2005, 29, 275-279.	0.9	32
320	Is alcoholic hepatitis an indication for transplantation? Current management and outcomes. Liver Transplantation, 2005, 11, S21-S24.	2.4	35
321	Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. The Cochrane Library, 2005, , CD000345.	2.8	13
322	Corticosteroids for alcoholic hepatitis—what's next?. Journal of Hepatology, 2005, 43, 526-533.	3.7	46
323	Impaired expression of the peroxisome proliferator–activated receptor alpha during hepatitis C virus infection. Gastroenterology, 2005, 128, 334-342.	1.3	194
324	A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology, 2004, 39, 1390-1397.	7.3	371

#	Article	IF	CITATIONS
325	Evaluation of amantadine in chronic hepatitis C: a meta-analysis. Journal of Hepatology, 2004, 41, 462-473.	3.7	68
326	Mesenteric adenitis and portal vein thrombosis due to Fusobacterium nucleatum. European Journal of Gastroenterology and Hepatology, 2004, 16, 1063-1066.	1.6	22
327	Long-term results of percutaneous management for anastomotic biliary stricture after orthotopic liver transplantation. Liver Transplantation, 2003, 9, 394-400.	2.4	55
328	Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology, 2003, 38, 1363-1369.	7.3	110
329	A comparison of fibrosis progression in chronic liver diseases. Journal of Hepatology, 2003, 38, 257-265.	3.7	401
330	Surgical Clipping May Lead to Better Results than Coil Embolization: Results from a Series of 101 Consecutive Unruptured Intracranial Aneurysms. Neurosurgery, 2003, 52, 1280-1290.	1.1	69
331	Transvascular Coil Hooking Procedure to Retrieve an Unraveled Guglielmi Detachable Coil: Technical Note. Neurosurgery, 2002, 50, 912-915.	1.1	28
332	Prothrombin index decrease: a useful and reliable marker of extensive fibrosis?. European Journal of Gastroenterology and Hepatology, 2002, 14, 1057-1059.	1.6	10
333	Effect of terlipressin (Glypressin®) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study*. European Journal of Gastroenterology and Hepatology, 2002, 14, 153-158.	1.6	131
334	Interferon for interferon naive patients with chronic hepatitis C. The Cochrane Library, 2002, , CD000370.	2.8	50
335	Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitis. Journal of Hepatology, 2002, 36, 342-348.	3.7	57
336	Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. Journal of Hepatology, 2002, 36, 480-487.	3.7	319
337	Usefullness of routine analysis of ascites fluid at the time of therapeutic paracentesis in asymptomatic cirrhotic out patients. Journal of Hepatology, 2002, 36, 55.	3.7	1
338	IL-10 receptor and coreceptor expression in quiescent and activated hepatic stellate cells. American Journal of Physiology - Renal Physiology, 2002, 282, G981-G990.	3.4	37
339	Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. , 2002, , CD000345.		6
340	Ethanol Sclerotherapy of Venous Malformations: Evaluation of Systemic Ethanol Contamination. Journal of Vascular and Interventional Radiology, 2001, 12, 595-600.	0.5	123
341	Tumor necrosis factor soluble receptor p55 and lipid peroxidation in patients with acute alcoholic hepatitis. American Journal of Gastroenterology, 2001, 96, 3361-3367.	0.4	22
342	Interferon for acute hepatitis C. The Cochrane Library, 2001, , CD000369.	2.8	23

#	Article	IF	CITATIONS
343	Exacerbation of Alcoholic Liver Injury by Enteral Endotoxin in Rats. Hepatology, 2000, 32, 1008-1017.	7.3	256
344	Prospective analysis of aneurysm treatment in a series of 103 consecutive patients when endovascular embolization is considered the first option. Journal of Neurosurgery, 2000, 93, 175-182.	1.6	127
345	Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography in patients with renal failure. Transplantation Proceedings, 2000, 32, 432-433.	0.6	27
346	Crushed stents in benign left brachiocephalic vein stenoses. Journal of Vascular Surgery, 2000, 32, 392-396.	1.1	34
347	Corticosteroids efficacy in severe alcoholic hepatitis (AH): Retrospective analysis of individual data from the American ANF French randomized contolled trials. Gastroenterology, 2000, 118, A972.	1.3	0
348	Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. Journal of Hepatology, 2000, 32, 579-586.	3.7	114
349	Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography. European Radiology, 1999, 9, 128-136.	4.5	78
350	Focal nodular hyperplasia of the liver on ferumoxides-enhanced MR imaging: features on conventional spin-echo, fast spin-echo and gradient-echo pulse sequences. European Radiology, 1999, 9, 1535-1542.	4.5	24
351	Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology, 1999, 29, 257-263.	7.3	521
352	Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view. Gastroenterology, 1999, 116, 378-386.	1.3	255
353	CYTOKINES AND ALCOHOLIC HEPATITIS. Alcoholism: Clinical and Experimental Research, 1998, 22, 760-762.	2.4	1
354	Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology, 1998, 27, 868-872.	7.3	286
355	Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. Lancet, The, 1998, 351, 1930-1931.	13.7	83
356	Effect of terlipressine (Glypressine®) on hepatorenal syndrome (HRS) in cirrhotic patietns: Results of a pilot study. Gastroenterology, 1998, 114, A1214.	1.3	7
357	In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features Journal of Clinical Pathology, 1997, 50, 401-406.	2.0	181
358	Hepatic cirrhosis and kidney transplantation outcome. Transplantation Proceedings, 1997, 29, 2406.	0.6	9
359	Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Journal of Hepatology, 1997, 26, 312-324.	3.7	93
360	Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin. Journal of Viral Hepatitis, 1997, 4, 243-253.	2.0	14

#	Article	IF	CITATIONS
361	Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology, 1996, 110, 1847-1853.	1.3	267
362	Marked increase in serum CA 19-9 level in patients with alcoholic cirrhosis: report of four cases. European Journal of Gastroenterology and Hepatology, 1996, 8, 1129-1131.	1.6	13
363	Treatment of chronic hepatitis C by interferon for longer duration than six months. Digestive Diseases and Sciences, 1996, 41, 99S-102S.	2.3	16
364	Hepatorenal syndrome. Digestive Diseases and Sciences, 1996, 41, 1054-1056.	2.3	69
365	Histological features predictive of liver fibrosis in chronic hepatitis C infection Journal of Clinical Pathology, 1996, 49, 998-1004.	2.0	35
366	Quantification of apolipoprotein A-I and B messenger RNA in heavy drinkers according to liver disease. Hepatology, 1996, 23, 44-51.	7.3	2
367	A Multidimensional Case-Control Study of Dietary, Alcohol, and Tobacco Habits in Alcoholic Men with Chronic Pancreatitis. Pancreas, 1995, 10, 231-238.	1.1	77
368	Prevalence of Cholelithiasis According to Alcoholic Liver Disease: A Possible Role of Apolipoproteins Al and All. Alcoholism: Clinical and Experimental Research, 1995, 19, 75-80.	2.4	22
369	A Comparison of Three Interferon Alfa-2b Regimens for the Long-Term Treatment of Chronic Non-A, Non-B Hepatitis. New England Journal of Medicine, 1995, 332, 1457-1463.	27.0	452
370	Ischemic hepatitis due to obstructive sleep apnea. Gastroenterology, 1995, 109, 1682-1684.	1.3	68
371	Prednisone-interferon combination in the treatment of chronic hepatitis B: Direct and indirect metanalysis. Hepatology, 1994, 20, 1390-1398.	7.3	61
372	Interest and necessity of combined neuroradiological and neurosurgical treatment in some cases of dural arterio-venous fistulae. Acta Neurochirurgica, 1993, 121, 26-33.	1.7	16
373	Transforming growth factor beta 1: in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon Gut, 1993, 34, S146-S147.	12.1	21
374	Improvement of histological lesions by 18 months therapy with \$alpha;2B interferon (IFN 2B) in patients with chronic hepatitis C. A randomized clinical trial. Hepatology, 1993, 18, A90.	7.3	2
375	A Randomized Trial of Prednisolone in Patients with Severe Alcoholic Hepatitis. New England Journal of Medicine, 1992, 326, 507-512.	27.0	376
376	Hydrocephalus in Guillain-Barré Syndrome. European Neurology, 1991, 31, 426-427.	1.4	14
377	Sneddon's Syndrome: A Rare Cause of Diffuse Vasculopathy. A Case Report With Review of the Literature. Acta Clinica Belgica, 1990, 45, 107-112.	1.2	1